Mesna Baxter Healthcare

Mesna, the active ingredient in Mesna Baxter Healthcare, is a thiol compound presented as a sterile solution for intravenous and oral use. It is employed to protect the urinary bladder from toxicity caused by the chemotherapy agents cyclophosphamide and ifosfamide, reducing the risk of hemorrhagic cystitis in patients undergoing cancer treatment.

GNH USA supplies Mesna Baxter Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Mesna acts as a uroprotective agent that neutralises the toxic metabolite of certain alkylating chemotherapies. - Hemorrhagic cystitis associated with cyclophosphamide therapy: prevents bladder irritation and bleeding by binding acrolein. - Hemorrhagic cystitis associated with ifosfamide therapy: reduces the incidence of urinary tract toxicity during treatment. - General uroprotection during high‑dose alkylating chemotherapy: maintains urinary tract integrity and supports continued oncologic therapy.

Mesna is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate discomfort often reported during treatment. - Vomiting: occasional episodes, usually transient. - Rash or mild skin irritation: localized erythema or pruritus.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of breathing difficulty, swelling, or hypotension. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: extensive skin detachment requiring urgent care. - Hemolytic anemia: sudden drop in hemoglobin levels, especially in patients with G6PD deficiency. - Pulmonary edema: fluid accumulation in the lungs presenting with shortness of breath.

When using Mesna, clinicians should observe several safety measures. - Renal function monitoring: assess creatinine and urine output before and during therapy. - Adequate hydration: ensure patients receive sufficient intravenous fluids to promote urinary flushing. - Hypersensitivity caution: discontinue if signs of severe allergic reaction appear. - Pregnancy safety: category D; use only if benefits outweigh potential fetal risk. - Dose adjustment in renal impairment: modify regimen based on glomerular filtration rate. - Store at below 25°C: keep in original container, protect from moisture and direct sunlight.

Mesna may interact with other medicines that affect renal function or oxidative balance.

Major Interactions (Avoid): - Cisplatin: concurrent use can increase nephrotoxicity. - High‑dose methotrexate: combined renal stress may require dose modification.

Moderate Interactions (Monitor Closely): - Loop diuretics (e.g., furosemide): monitor electrolytes and fluid balance. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): watch for reduced renal clearance. - Warfarin: observe INR values for potential anticoagulation changes.